Routine Cycling of Antimicrobial Agents as an Infection-Control Measure

Fridkin, Scott K.
June 2003
Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1438
Academic Journal
Antimicrobial cycling is the deliberate, scheduled removal and substitution of specific antimicrobials or classes of antimicrobials within an institutional environment (either hospital-wide or confined to specific units) to avoid or reverse the development of antimicrobial resistance. True antimicrobial cycling requires a return to the antimicrobial(s) that were first used. Testing of the hypothesis that cycling will result in a lower prevalence of resistance is ongoing, mostly occurs within intensive care units, and largely involves cycling regimens targeted for treatment of suspected gram-negative bacterial infections. Unfortunately, there has been insufficient study to determine whether any meaningful impact on resistance has occurred as a result of a cycling program. Mathematical models question the usefulness of cycling as an infection-control method. Published studies demonstrate that cycling may be one way to change prescribing practices by clinicians without sacrificing patient safety. However, optimizing antimicrobial use through traditional and novel methods (e.g., computer decision support) should not be abandoned.


Related Articles

  • Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. Kollef, Mann H. // Clinical Infectious Diseases;9/15/2008 Supplement 1, Vol. 47, pS1 

    The article discusses various reports published within the issue, including the article about the use of broad spectrum antimicrobials in treating bacterial infections and another on the pharmacokinetic and pharmacodynamic properties of meropenem.

  • Moxifloxacin. Barman Balfour, J.A.; Wiseman, L.R. // Drugs;Mar1999, Vol. 57 Issue 3, p363 

    â–´ Moxifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing Gram-negative and Gram-positive bacteria. It has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with...

  • Levofloxacin: A Review of its Use in the Treatment of Bacterial Infections in the United States. Croom, Katherine F.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 24, p2769 

    Levofloxacin (Levaquin[sup ®]) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens. It is active against both penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae....

  • Tuning natural antimicrobials to improve their effectiveness at battling superbugs.  // Biomedical Market Newsletter;9/12/2011, Vol. 21, p479 

    The article reports on a study at the Institute of Food Research which explores the use of virus-produced proteins that destroy bacterial cells to fight against dangerous microbial infections.

  • Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Kollef, Marin H. // Clinical Infectious Diseases;9/1/2000 Supplement 3, Vol. 31, pS131 

    Discusses inadequate antimicrobial treatment as an important factor in the emergence of infections due to antibiotic-resistant bacteria. Factors that contribute to inadequate antimicrobial treatment of hospitalized patients; Strategies to minimize inadequate treatment; Use of empirical...

  • Antibiotic Therapy for Bacterial Enterocolitis: A Comprehensive Review. Wolf, David C.; Giannella, Ralph A. // American Journal of Gastroenterology;Oct1993, Vol. 88 Issue 10, p1667 

    The treatment of bacterial enterocolitis is a major health care issue throughout the world. Many cases of diarrhea due to invasive bacterial pathogens can be managed by oral rehydration, only. Nonetheless, antibiotics play an invaluable role in the management of patients suffering from severe...

  • Gatifloxacin: A Review of its Use in the Treatment of Bacterial Infections in the US. Keam, Susan J.; Croom, Katherine F.; Keating, Gillian M. // Drugs;2005, Vol. 65 Issue 5, p695 

    Gatifloxacin (Tequin®) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis,...

  • Antibiotics: Knowing when they're not needed. Johnson, Teddi Dineley // Nation's Health;Oct2010, Vol. 40 Issue 8, p15 

    The article emphasizes the need for patients and parents to be aware of the limitations of antibiotic treatments, because taking antibiotics when they are not needed or misusing them increases the risk that an infection a patient will get later will be resistant to these treatments. It cites...

  • Antimicrobials: Killing persisters while they sleep. Jermy, Andrew // Nature Reviews Microbiology;Jul2011, Vol. 9 Issue 7, p482 

    The article highlights a study entitled "Metabolite-enabled eradication of bacterial persisters by aminoglycosides," by J. J. Collins and colleagues. They show that the addition of certain metabolites can enhance the killing of both gram-negative and gram-positive persisters by aminoglycosides....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics